231 related articles for article (PubMed ID: 30385883)
21. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
22. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
23. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L; Smith TJ; Janssen JAMJL
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
[TBL] [Abstract][Full Text] [Related]
24. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
25. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
26. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
27. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
[TBL] [Abstract][Full Text] [Related]
28. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
[TBL] [Abstract][Full Text] [Related]
29. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA.
Zhao SX; Tsui S; Cheung A; Douglas RS; Smith TJ; Banga JP
J Endocrinol; 2011 Sep; 210(3):369-77. PubMed ID: 21715431
[TBL] [Abstract][Full Text] [Related]
30. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
31. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.
Wang Y; Smith TJ
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1735-48. PubMed ID: 24651704
[TBL] [Abstract][Full Text] [Related]
32. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation.
Smith TJ
Autoimmunity; 2003; 36(6-7):409-15. PubMed ID: 14669949
[TBL] [Abstract][Full Text] [Related]
33. Immunological Aspects of Graves' Ophthalmopathy.
Łacheta D; Miśkiewicz P; Głuszko A; Nowicka G; Struga M; Kantor I; Poślednik KB; Mirza S; Szczepański MJ
Biomed Res Int; 2019; 2019():7453260. PubMed ID: 31781640
[TBL] [Abstract][Full Text] [Related]
34. Increased generation of fibrocytes in thyroid-associated ophthalmopathy.
Douglas RS; Afifiyan NF; Hwang CJ; Chong K; Haider U; Richards P; Gianoukakis AG; Smith TJ
J Clin Endocrinol Metab; 2010 Jan; 95(1):430-8. PubMed ID: 19897675
[TBL] [Abstract][Full Text] [Related]
35. Cambridge Ophthalmological Symposium 2018: introduction and reflections on the day.
Ludgate M
Eye (Lond); 2019 Feb; 33(2):169-173. PubMed ID: 30568255
[TBL] [Abstract][Full Text] [Related]
36. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Kumar S; Coenen M; Iyer S; Bahn RS
Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
Khoo TK; Bahn RS
Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
[TBL] [Abstract][Full Text] [Related]
39. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
40. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
